Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

Media formats available:

Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
The effect of icosapent ethyl on CV events in metabolic syndrome
Diabetes
The effect of icosapent ethyl on CV events in metabolic syndrome
- Michael Miller, MD
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
- Aaron Wong, MD

PACE-CME